Could IRAEs share etiology with sudden onset Guillain-Barré syndromes after viral infections, or similar neuropathies and myopathies? Should greater consideration for safety also be adopted before mass innoculation with novel antigen-presenting biologics - lentoviral vectors derived from HIV plasmids - 2-strain adenoviral vectors for prime and boost - self-adjuvanting mRNA shots coding for both epitope and cytokine in same preparation, developed to combat the 2020 corona virus pandemic?
